Institut National Supérieur des Sciences Agronomiques de l’Alimentation et de l'Environnement has identified compounds reported to be useful for the treatment of cryptosporidiosis.
Shemyakin Institute of Bioorganic Chemistry has synthesized perylenylethynylphenol derivatives acting as photosensitizers for photodynamic therapy reported to be useful for the treatment of SARS-CoV-2 infection (COVID-19).
Visceral leishmaniasis is a fatal disease caused by the Leishmania parasite, affecting organs such as the liver and spleen. Visceral leishmaniasis is considered a neglected tropical disease and is estimated to cause between 50,000 and 90,000 cases and around 70,000 deaths per year.
Centre Hospitalier Regional Universitaire de Lille, Centre National de la Recherche Scientifique, INSERM, Institut Pasteur de Lille and the University of Lille have prepared and tested new tricyclic spirolactam compounds reported to be useful for the treatment of tuberculosis.
Evaxion A/S has added a new vaccine program, named EVX-B4, to its pipeline for prevention of group A Streptococcus (GAS) infections. Invasive GAS infections can cause diseases such as sepsis, toxic shock, rheumatic heart disease and necrotizing fasciitis.
Scientiam Pharma has disclosed new 6-aminophenanthridine derivatives acting as Epstein-Barr nuclear antigen 1 (EBNA-1) inhibitors reported to be useful for the treatment of Epstein-Barr virus (EBV)-associated disorders such as post-transplant lymphoproliferative disorder, multiple sclerosis and infectious mononucleosis.
CNCCS SCARL Collezione Nazionale Dei Composti Chimici E Centro Screening and IRBM SpA have prepared new serine protease NS3/non-structural protein 2B (NS3/NS2B) (dengue virus) and/or (West Nile virus) and/or (Zika virus) and/or Japanese encephalitis virus inhibitors.
A global consortium led by Adaptvac ApS aims to design and test a new vaccine that could offer broad protection against several filoviruses, including Zaire ebolavirus, Sudan ebolavirus and Marburg virus.
RSS
